

Appl. No. 09/719,867
Amdt. dated June 13, 2006
Reply to Office Action of February 13, 2006

Amendments to the Claims

This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims

Claim 1 (cancelled).

Claim 2 (cancelled).

Claim 3 (withdrawn): Mutations in *Neisseria gonorrhoeae* GyrA associated with quinolone resistance selected from: Asp90 to Glu, Ser91 to Cys, Asp95 to His, Glu161 to Gly, Glu161 to Lys, Asn65 to His, Asp80 to Gly, and Glu62 to Lys.

Claim 4 (currently amended): The use of the process according to Claim ~~1~~ 37 for identifying and characterizing drug-target interactions.

Claim 5 (currently amended): A process for identifying and characterizing one or more mutations that confer resistance to a compound -a- comprising:
generating overlapping PCR products under PCR conditions that allow for mutation wherein said PCR products are of approximately 10 kb to approximately 15 kb which overlapping PCR products encompass the complete chromosome from a wild-type bacteria strain for which the chromosomal sequence is known, ~~under conditions that allow for mutation of the fragments;~~
allowing one or more of the generated PCR products to be incorporated into the chromosome of wild-type bacteria;
isolating bacterial strains that demonstrate resistance to a compound; and
identifying the mutation responsible for the resistance.

Claim 6 (currently amended): A process for identifying one or more mutations that confer resistance to a compound comprising:

Appl. No. 09/719,867

Amdt. dated June 13, 2006

Reply to Office Action of February 13, 2006

- a) generating overlapping PCR products of approximately 10 kb to ~~approximately~~ ~~pproximately~~ 15 kb which encompass the complete chromosome from a strain of bacteria which demonstrates resistance to a compound;
- b) allowing one or more of the generated PCR products to be incorporated into the chromosome of a wild-type bacteria; and
- c) isolating bacterial strains that demonstrate resistance to the compound; and identifying the mutation responsible for the resistance.

Claim 7 (cancelled).

Claim 8 (currently amended): The process of claim 1 ~~37~~ where the bacteria is from the group of genus *Neisseria*, *Haemophilus*, *Streptococcus*, *Staphylococcus*, or *Escherichia*.

Claim 9 (currently amended): The process of claim 5 or 6 where said ~~the~~ bacteria is from the group of *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Haemophilus influenzae*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, or *Escherichia coli*.

Claim 10 (previously presented): The process of claim 5 where the compound is a fluoroquinolone.

Claim 11 (previously presented): The process of claim 5 where the compound is ciprofloxacin.

Claim 12 (previously presented): The process of claim 5 where the compound is clinafloxacin.

Claim 13 (previously presented): The process of claim 5 where the compound is dihydroxydiphenylether (DHDPE).

Appl. No. 09/719,867
Amdt. dated June 13, 2006
Reply to Office Action of February 13, 2006

Claim 14 (previously presented): The process of claim 5 where the compound is Triclosan.

Claim 15 (cancelled):

Claim 16 (currently amended): The process of claim + 37 in which the compound inhibits the growth or survival of the wild-type bacteria under any condition.

Claim 17 (currently amended): The process of claim + 37 in which the compound inhibits the growth or survival of the wild-type bacteria in culture.

Claim 18 (currently amended): The process of claim + 37 in which the compound inhibits the growth or survival of the wild-type bacteria in an animal host.

Claim 19 (currently amended): The process of claim + 37 in which the compound is an inhibitor of type II topoisomerases.

Claim 20 (currently amended): The process of claim + 37 in which the compound is an inhibitor of FabI.

Claim 21 (currently amended): The process of claim + 37 in which the compound is an inhibitor of enzymes involved in fatty acid biosynthesis.

Claim 22 (previously presented): The process of claim 6 in which a strain of bacteria which demonstrates resistance to a compound was isolated from a culture that had been treated with a chemical mutagen.

Claim 23 (previously presented): The process of claim 6 in which a strain of bacteria which demonstrates resistance to a compound was isolated from a culture that had been treated with ultraviolet light.

Claim 24 (previously presented): The process of claim 6 in which a strain of bacteria which demonstrate resistance to a compound was isolated from a culture that had

Appl. No. 09/719,867

Amdt. dated June 13, 2006

Reply to Office Action of February 13, 2006

been subjected to a mutagenic protocol that consisted of insertion of DNA into the chromosome of the bacteria.

Claim 25 (withdrawn): Bacteria comprising a protein in which a contiguous stretch of 40 amino acids is at least 30% identical to residues 75 to 114 of the *Neisseria gonorrhoeae* GyrA and the residue analogous to:

62 is lysine or

63 is arginine or glutamic acid or

65 is histidine or

135 is valine or

161 is glutamic acid or lysine or glycine.

Claim 26 (withdrawn): *Escherichia coli* strains comprising a GyrA protein in which the amino acid analogous to the *Neisseria gonorrhoeae* GyrA amino acid

62 is lysine or

63 is arginine or glutamic acid or

65 is histidine or

135 is valine or

161 is glutamic acid or lysine or glycine.

Claim 27 (withdrawn): *Neisseria gonorrhoeae* strains comprising a GyrA protein in which the amino acid residue

62 is lysine, or

63 is arginine or glutamic acid, or

65 is histidine, or

80 is alanine or glycine, or

90 is arginine or glutamic acid, or

91 is tyrosine or alanine or cysteine, or

92 is proline, or

95 is arginine or alanine or valine or tyrosine or histidine or glycine, or

114 is histidine, or

Appl. No. 09/719,867

Amdt. dated June 13, 2006

Reply to Office Action of February 13, 2006

135 is valine, or

161 is glutamic acid or lysine or glycine.

Claim 28 (withdrawn): *Neisseria gonorrhoeae* strains selected from the group consisting of NG-2707, GC318, NG-2721, NG-2711, NG-2706, NG-2717, NG-2687, GC158, NG-2690, GC219, GC291, NG-2691, NG-2720, NG-2723, GC156, NG-2698, NG-2709, NG2716, NG-2719, and NG-2712.

Claim 29 (withdrawn): A protein comprising in which a contiguous stretch of 40 amino acids is at least 30% identical to residues 75 to 114 of the *Neisseria gonorrhoeae* GyrA and the residue analogous to:

62 is lysine or

63 is arginine or glutamic acid or

65 is histidine or

135 is valine or

161 is glutamic acid or lysine or glycine.

Claim 30 (withdrawn): *Neisseria gonorrhoeae* GyrA protein comprising amino acid substitutions when residue

62 is lysine, or

63 is arginine or glutamic acid, or

65 is histidine, or

80 is alanine or glycine, or

90 is arginine or glutamic acid, or

91 is tyrosine or alanine or cysteine, or

92 is proline, or

95 is arginine or alanine or valine or tyrosine or histidine or glycine, or

114 is histidine, or

135 is valine, or

161 is glutamic acid or lysine or glycine.

Appl. No. 09/719,867

Amdt. dated June 13, 2006

Reply to Office Action of February 13, 2006

Claim 31 (withdrawn): Bacteria comprising a protein that is at least 30% identical to the sequence of the *Neisseria gonorrhoeae* FabI protein in which the amino acid residue corresponding to

15 is valine, or

20 is threonine, or

23 is glycine, or

25 is valine, or

51 is threonine, or

91 is threonine, or

93 is cysteine or serine, or

95 is valine, or

104 is leucine, or

105 is histidine, or

144 is valine, or

147 is histidine, or

159 is alanine, or

160 is isoleucine, or

162 is valine, or

193 is asparagine or valine, or

201 is valine, or

203 is tyrosine or valine, or

204 is serine or leucine or isoleucine or valine, or

212 is threonine or valine, or

247 is asparagine.

Claim 32 (withdrawn): A *Neisseria gonorrhoeae* strain selected from the group consisting of NG-2669, NG-2654, NG-2651, NG-2670, NG-2660, NG-2641, NG-2639, NG-2638, NG-2640, NG-2648, NG-2657, NG-2656, NG-2653, NG-2658, NG-2663, NG-2642, NG-2671, NG-2652, NG-2661, NG-2644, NG-2667, NG-

Appl. No. 09/719,867

Amdt. dated June 13, 2006

Reply to Office Action of February 13, 2006

2665, NG-2655, NG-2643, NG-2666, NG-2664, NG-2647, NG-2646, NG-2650,
NG-2649, NG-2645, NG-2659, NG-2662, and NG-2672.

Claim 33 (withdrawn): An *Escherichia coli* strain comprising a FabI protein with the amino acids analagous to the ones described in claim 31 with the exception of mutations resulting in changing residue 93 to alanine or serine or cysteine or valine, 159 to threonine, or 203 to leucine.

Claim 34 (withdrawn): A protein comprising at least 30% identical to the sequence of the *Neisseria gonorrhoeae* FabI protein in which the amino acid residue corresponding to 15 is valine, or 20 is threonine, or 23 is glycine, or 25 is valine, or 51 is threonine, or 91 is threonine, or 93 is cysteine or serine, or 95 is valine, or 104 is leucine, or 105 is histidine, or 144 is valine, or 147 is histidine, or 159 is alanine, or 160 is isoleucine, or 162 is valine, or 193 is asparagine or valine, or 201 is valine, or

Appl. No. 09/719,867

Amtd. dated June 13, 2006

Reply to Office Action of February 13, 2006

203 is tyrosine or valine, or

204 is serine or leucine or isoleucine or valine, or

212 is threonine or valine, or

247 is asparagine.

Claim 35 (withdrawn): A *Neisseria gonorrhoeae* FabI protein comprising the amino acid corresponding to residue:

15 is valine, or

20 is threonine, or

23 is glycine, or

25 is valine, or

51 is threonine, or

91 is threonine, or

93 is cysteine or serine, or

95 is valine, or

104 is leucine, or

105 is histidine, or

144 is valine, or

147 is histidine, or

159 is alanine, or

160 is isoleucine, or

162 is valine, or

193 is asparagine or valine, or

201 is valine, or

203 is tyrosine or valine, or

204 is serine or leucine or isoleucine or valine, or

212 is threonine or valine, or

247 is asparagine.

Claim 36 (previously presented): A process of screening compounds for antibacterial

Appl. No. 09/719,867

Amdt. dated June 13, 2006

Reply to Office Action of February 13, 2006

activity comprising:

- a) identifying the mutation that confers resistance to a compound using the method of Claim 1, Claim 5, or Claim 6;
- b) contacting a strain of bacteria containing the mutation with a compound; and
- c) evaluating the compound for antibacterial activity.

Claim 37 (new): A process for identifying one or more mutations that confer resistance to a compound comprising:

- a) generating overlapping PCR products containing random point mutations which PCR products encompass the complete chromosome of a wild-type strain of bacteria for which the chromosomal sequence is known;
- b) isolating PCR products of step (a) of approximately 10 kb to approximately 15 kb;
- c) preparing pools of the PCR products from step (a) corresponding to about 100 kb of the chromosome;
- d) transforming the wild-type strain of the bacteria with said pools prepared in step (c) and isolating the resulting bacterial strains that are resistant to a compound;
- e) isolating individual PCR products from the resultant strains isolated in step (d);
- f) transforming the wild-type strain with a PCR product from a resistant strain isolated in step (d) and isolating the resulting strains that are resistant to the compound;
- g) generating smaller PCR products of approximately 1 to approximately 4 kb which encompass the PCR product from at least one resultant strain identified in step (f);
- h) transforming a wild-type strain with one of the smaller PCR products from step (g) and determining whether the strain is resistant to the compound;

Appl. No. 09/719,867

Amtdt. dated June 13, 2006

Reply to Office Action of February 13, 2006

- i) repeating step (h) for each of the smaller PCR products until a strain resistant to the compound is found or until all of the smaller PCR products have been evaluated; and
- j) sequencing the smaller PCR product isolated from a strain resistant to the compound and comparing the sequence to the corresponding sequence in a wild-type strain to determine the mutation or mutations that confer resistance to a compound.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☒ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.